Valuation: DBV Technologies

Market Cap 71Cr 81Cr 66Cr 60Cr 113.94Cr 7.75TCr 115.71Cr 774.65Cr 304.03Cr 3.86TCr 305.03Cr 298.33Cr 13TCr P/E 2026 *
-4.86x
P/E 2027 * -16.7x
Enterprise Value 63Cr 73Cr 59Cr 54Cr 101.76Cr 6.92TCr 103.34Cr 691.86Cr 271.53Cr 3.45TCr 272.43Cr 266.45Cr 12TCr EV / Sales 2026 *
246x
EV / Sales 2027 * 9.73x
Free-Float
99.85%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 66 29/11/2018
Director of Finance/CFO 56 06/11/2023
Chief Operating Officer - 01/12/2023
Director TitleAgeSince
Director/Board Member 51 21/10/2015
Director/Board Member 62 21/06/2016
Director/Board Member 60 15/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 81Cr
+0.55%-0.38%+67.14%+22.43% 32TCr
+0.21%+2.87%+29.78%-10.42% 7.15TCr
-0.90%+0.82%+37.74%+92.27% 988.05Cr
-3.60%-1.52%-0.43%-5.11% 870Cr
+1.80%-0.88%-20.84%-3.30% 425.44Cr
-0.68%+2.94%-38.65%+11.36% 386.28Cr
+3.08%-5.35%-9.43%+0.75% 347.02Cr
-2.27%-3.38%+27.18%+45.45% 264.72Cr
+0.85%+5.41%-3.94%-4.52% 222.54Cr
Average -0.08%+2.05%+9.84%+16.55% 4.75TCr
Weighted average by Cap. +0.42%+4.48%+55.76%+17.45%

Financials

2026 *2027 *
Net sales 25.61L 29.46L 23.84L 21.89L 41.33L 28Cr 41.97L 2.81Cr 1.1Cr 14Cr 1.11Cr 1.08Cr 47Cr 7.02Cr 8.08Cr 6.54Cr 6Cr 11Cr 771.3Cr 12Cr 77Cr 30Cr 383.99Cr 30Cr 30Cr 1.29TCr
Net income -17Cr -20Cr -16Cr -15Cr -28Cr -1.91TCr -29Cr -191Cr -75Cr -951.74Cr -75Cr -74Cr -3.19TCr -12Cr -13Cr -11Cr -9.91Cr -19Cr -1.27TCr -19Cr -127.26Cr -50Cr -634.14Cr -50Cr -49Cr -2.13TCr
Net Debt -7.55Cr -8.68Cr -7.02Cr -6.45Cr -12Cr -828.66Cr -12Cr -83Cr -32Cr -412.54Cr -33Cr -32Cr -1.38TCr -2.27Cr -2.61Cr -2.11Cr -1.94Cr -3.66Cr -249.28Cr -3.72Cr -25Cr -9.77Cr -124.1Cr -9.81Cr -9.59Cr -416.14Cr
Logo DBV Technologies
DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-